An objective of the present invention is to provide a means for enabling cancer immunotherapy that targets approximately 30% of various cancer patients that highly express forkhead box M1 (FOXM1) among the Japanese, by identifying FOXM1-derived peptides that can activate cancer cell-damaging human killer T cells by binding to HLA-A2. The present invention provides a peptide of (A) or (B) below:(A) a peptide including the amino acid sequence of any one of SEQ ID NOs: 1 to 3；(B) a peptide which includes the amino acid sequence of any one of SEQ ID NOs: 1 to 3,wherein one, two, or several amino acid(s) are substituted, deleted, inserted, and/or added, andwherein the peptide shows cytotoxic (killer) T cell-inducing activity.
